Bicara Therapeutics Inc.

Stage 4 · Declining · week 1

As of Oct 22, 2026, Bicara Therapeutics is in Stage 4, the downtrend phase, now in its first week (since Oct 21, 2026). It closed at $17.61, 42.1% below its 52-week high and below its 200-day average, which is rising.

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. More about the company

$17.61

-1.68% today

$1.2B · Small cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is BCAX early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2024-09-13 → 2026-10-22

S? 42w

S2 13w

S2 26w

2024-09-132026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S? 42w → S4 8w → S1 6w → S2 13w → S3 1w → S2 3w → S3 4w → S2 26w → S3 5w → S4 1w current

Total tracked: 109 weeks across 10 stage runs.

BCAX among Biotechnology182nd of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…182	BCAXBicara Therapeutics Inc.	Stage 4 · wk 1	57	−14.0%

vs 52W High

-42.1%

$13.93 lo$30.40 hi

42.1% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 1

1w13w26w

Week 1, early Stage 4 decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-17.4%

200 DMA: $21.33 · rising

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

1.21x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-14.0%

-34.8%

-22.9%

YTD

+7.5%

+3.2%

Scan Membership

Not in any current scan.

Recent Stage Timeline

2026-10-22S4

Wk 1 · Vol 1.21x

2026-10-21S43→4

Wk 1 · Vol 0.75x

2026-10-20S3

Wk 6 · Vol 0.70x

2026-10-19S3

Wk 5 · Vol 1.24x

2026-10-16S3

Wk 5 · Vol 1.17x

2026-10-15S3

Wk 5 · Vol 0.94x

2026-10-14S3

Wk 5 · Vol 2.07x

2026-10-13S3

Wk 5 · Vol 1.89x

2026-10-12S3

Wk 4 · Vol 0.98x

2026-10-09S3

Wk 4 · Vol 1.06x

2026-10-08S3

Wk 4 · Vol 1.90x

2026-10-07S3

Wk 4 · Vol 1.41x

Moving averages & range

50 DMA

$21.10

200 DMA

$21.33

52W High

$30.40

52W Low

$13.93

5D Low

$16.78

Resistance levels (recent highs)

20d High

$19.21

60d High

$28.06

120d High

$30.40

250d High

$30.40

Next resistance

+9.1%

to 20d High

ROE

-41.0%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 2.5

Bicara Therapeutics: quick answers

What stage is Bicara Therapeutics in?

As of Oct 22, 2026, Bicara Therapeutics (BCAX) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 21, 2026 and is in its first week there. What the four stages mean

Is Bicara Therapeutics in an uptrend?

No. Bicara Therapeutics is in a Stage 4 downtrend. It trades 17.4% below its 200-day average, which is rising.

How far is Bicara Therapeutics from its 52-week high?

Bicara Therapeutics closed at $17.61 on Oct 22, 2026, 42.1% below its 52-week high of $30.40. Its 52-week low is $13.93.

How has Bicara Therapeutics performed over the past year?

As of Oct 22, 2026, Bicara Therapeutics is up 3.2% over the past year and up 7.5% so far in 2026.

Which sector and industry is Bicara Therapeutics in?

Bicara Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.